Actionable news
All posts from Actionable news
Actionable news in CELG: Celgene Corporation,

Market Access Impact: Myeloma (US)

LONDON, Nov. 17, 2016 /PRNewswire/ -- Market barriers affect nearly 20% of myeloma prescriptions. Is your brand losing market share?
We surveyed 150 European oncologists and haematologists to find out how market barriers affect the way they prescribe 8 myeloma drugs. The results show that half of those treatments lose market share overall while the other half make small net gains.
Find out why, and learn what your brand can do to regain lost share, in Market Access Impact: Myeloma (EU5).
The report covers major brands from Amgen, BMS/AbbVie, Celgene, Johnson & Johnson, and Novartis. You'll discover which brands see the biggest gains and losses from 7 different market barriers, which barriers help and hurt your brand the most, and which competitors you take share from and lose it to.

Top Takeaways

Half of brands are widely prescribed: Around 70% or more of the doctors surveyed prescribe 4 of the 8 brands covered. Over 90% of doctors prescribe the top brand.
Half of the surveyed...